^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MAP3K8 overexpression

    i
    Other names: MAP3K8, Mitogen-Activated Protein Kinase Kinase Kinase 8, , Tumor Progression Locus 2, Proto-Oncogene C-Cot, MEKK8, Tpl-2 , C-COT, ESTF, COT, EST, Proto-Oncogene Serine/Threoine Protein Kinase, Augmented In Rheumatoid Arthritis 2, Cot (Cancer Osaka Thyroid) Oncogene, Serine/Threonine-Protein Kinase Cot, Cancer Osaka Thyroid Oncogene, Ewing Sarcoma Transformant, MAP3K8, AURA2, TPL-2, TPL2
    Entrez ID:
    1326
    over4years
    Effect of MAP3K8 on Prognosis and Tumor-Related Inflammation in Renal Clear Cell Carcinoma. (PubMed, Front Genet)
    PPI network and functional enrichment analyses revealed that MAP3K8 correlated with NFKBIZ, MIAT, PARP15, CHFR, MKNK1, and ERMN, which was mainly involved in I-kappaB kinase/NF-kappaB and toll-like receptor signaling pathways. MAP3K8 overexpression was correlated with damaged survival in ccRC and may play a crucial role in cancer-related inflammation via I-kappaB kinase/NF-kappaB and toll-like receptor signaling pathways.
    Journal • PARP Biomarker • IO biomarker
    |
    IKBKE (Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Epsilon) • MAP3K8 (Mitogen-Activated Protein Kinase Kinase Kinase 8)
    |
    MAP3K8 overexpression